Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Dec 2:11:80.
doi: 10.1186/1471-2318-11-80.

Rationale and design of the B-PROOF study, a randomized controlled trial on the effect of supplemental intake of vitamin B12 and folic acid on fracture incidence

Janneke P van Wijngaarden  1 , Rosalie A M Dhonukshe-Rutten, Natasja M van Schoor, Nathalie van der Velde, Karin M A Swart, Anke W Enneman, Suzanne C van Dijk, Elske M Brouwer-Brolsma, M Carola Zillikens, Joyce B J van Meurs, Johannes Brug, André G Uitterlinden, Paul Lips, Lisette C P G M de Groot
Affiliations
Randomized Controlled Trial

Rationale and design of the B-PROOF study, a randomized controlled trial on the effect of supplemental intake of vitamin B12 and folic acid on fracture incidence

Janneke P van Wijngaarden et al. BMC Geriatr. .

Abstract

Background: Osteoporosis is a major health problem, and the economic burden is expected to rise due to an increase in life expectancy throughout the world. Current observational evidence suggests that an elevated homocysteine concentration and poor vitamin B12 and folate status are associated with an increased fracture risk. As vitamin B12 and folate intake and status play a large role in homocysteine metabolism, it is hypothesized that supplementation with these B-vitamins will reduce fracture incidence in elderly people with an elevated homocysteine concentration.

Methods/design: The B-PROOF (B-Vitamins for the PRevention Of Osteoporotic Fractures) study is a randomized double-blind placebo-controlled trial. The intervention comprises a period of two years, and includes 2919 subjects, aged 65 years and older, independently living or institutionalized, with an elevated homocysteine concentration (≥ 12 μmol/L). One group receives daily a tablet with 500 μg vitamin B12 and 400 μg folic acid and the other group receives a placebo tablet. In both tablets 15 μg (600 IU) vitamin D is included. The primary outcome of the study is osteoporotic fractures. Measurements are performed at baseline and after two years and cover bone health i.e. bone mineral density and bone turnover markers, physical performance and physical activity including falls, nutritional intake and status, cognitive function, depression, genetics and quality of life. This large multi-center project is carried out by a consortium from the Erasmus MC (Rotterdam, the Netherlands), VUmc (Amsterdam, the Netherlands) and Wageningen University, (Wageningen, the Netherlands), the latter acting as coordinator.

Discussion: To our best knowledge, the B-PROOF study is the first intervention study in which the effect of vitamin B12 and folic acid supplementation on osteoporotic fractures is studied in a general elderly population. We expect the first longitudinal results of the B-PROOF intervention in the second semester of 2013. The results of this intervention will provide evidence on the efficacy of vitamin B12 and folate supplementation in the prevention of osteoporotic fractures.

Trial registration: The B-PROOF study is registered with the Netherlands Trial (NTR NTR1333) and with ClinicalTrials.gov (NCT00696514).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Recruitment and baseline measurements in participants of the B-PROOF study.
See this image and copyright information in PMC

References

    1. Consensus development conference. diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646–650. - PubMed
    1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos int. 2006;17(12):1726–1733. doi: 10.1007/s00198-006-0172-4. - DOI - PubMed
    1. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos int. 2005;16(3):229–238. doi: 10.1007/s00198-004-1811-2. - DOI - PubMed
    1. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos int. 2008;19(4):399–428. doi: 10.1007/s00198-008-0560-z. - DOI - PMC - PubMed
    1. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293(18):2257–2264. doi: 10.1001/jama.293.18.2257. - DOI - PubMed

Publication types

Associated data